The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Rivastigmine for Dementia Associated with Parkinson's Disease
Open accessAbstract
BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients. METHODS: Patients in whom mild-to-moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or 3 to 12 mg of rivastigmine per day for 24 weeks. Primary efficacy variables were the scores for the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change (ADCS-CGIC). Secondary clinical outcomes were the scores for the Alzheimer's Disease Cooperative Study-Activities of Daily Living, the 10-item Neuropsychiatric Inventory, the Mini-Mental State Examination, Cognitive Drug Research power of attention tests, the Verbal Fluency test, and the Ten Point Clock-Drawing test. RESULTS: A total of 541 patients were enrolled, and 410 completed the study. The outcomes were better among patients treated with rivastigmine than among those who received placebo; however, the differences between these two groups were moderate and similar to those reported in trials of rivastigmine for Alzheimer's disease. Rivastigmine-treated patients had a mean improvement of 2.1 points in the score for the 70-point ADAS-cog, from a baseline score of 23.8, as compared with a 0.7-point worsening in the placebo group, from a baseline score of 24.3 (P<0.001). Clinically meaningful improvements in the scores for the ADCS-CGIC were observed in 19.8 percent of patients in the rivastigmine group and 14.5 percent of those in the placebo group, and clinically meaningful worsening was observed in 13.0 percent and 23.1 percent, respectively (mean score at 24 weeks, 3.8 and 4.3, respectively; P=0.007). Significantly better outcomes were seen with rivastigmine with respect to all secondary efficacy variables. The most frequent adverse events were nausea (affecting 29.0 percent of patients in the rivastigmine group and 11.2 percent of those in the placebo group, P<0.001), vomiting (16.6 and 1.7 percent, P<0.001), and tremor (10.2 and 3.9 percent, P=0.01). CONCLUSIONS: In this placebo-controlled study, rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a double-blind clinical trial in which individuals were randomly assigned to receive rivastigmine (362 individuals) or the placebo (172 individuals), participants treated with rivastigmine had increased scores (mean improvement of 2.1 points) on the 70-point Alzheimer’s Disease Assessment Scale, whereas those in the placebo group had decreased scores (decrease of 0.7 points) (P < 0.001).446”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [446]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Self-citationDelis-Kaplan Executive Function System
Delis, D. C., Kaplan, E., & Kramer, J. H. (2012) · PsycTESTS Dataset · doi:10.1037/t15082-000 · Cited by 2,683
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study
Aarsland, D., Andersen, K., Larsen, J. P., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,401
Self-citationWhat contributes to quality of life in patients with Parkinson's disease?
Schrag, A. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.308 · Cited by 1,380
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Self-citationSydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Galasko, D. R., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. H. (1997) · PubMed · Cited by 767
McKeith, I. G. (2004) · Europe PMC (PubMed Central) · Cited by 756
Dementia associated with Parkinson's disease
Emre, M. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00351-x · Cited by 685
Self-citationSchneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
McKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., Dickson, D., Dubois, B., Duda, J. E., Feldman, H., et al. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00619-7 · Cited by 618
Self-citationPerry, E. K., Curtis, M., Dick, D. J., Candy, J. M., Atack, J. R., Bloxham, C. A., Blessed, G., Fairbairn, A., Tomlinson, B. E., & Perry, R. H. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.413 · Cited by 571
Bohnen, N. I., Kaufer, D. I., Ivanco, L. S., Lopresti, B., Koeppe, R. A., Davis, J. G., Mathis, C. A., Moore, R. Y., & DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1745 · Cited by 551
Mental symptoms in Parkinson's disease are important contributors to caregiver distress
Aarsland, D., Larsen, J. P., Karlsen, K., Lim, N. G., & Tandberg, E. (1999) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199910)14:10<866::aid-gps38>3.0.co;2-z · Cited by 487
Self-citation(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Parkinson Disease Neuropathology: Later-Developing Dementia and Loss of the Levodopa Response
Apaydin, H., Ahlskog, J. E., Parisi, J. E., Boeve, B. F., & Dickson, D. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.1.102 · Cited by 399
The role of radiotracer imaging in Parkinson disease
Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 374
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough
Lang, A. E., & Obeso, J. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00740-9 · Cited by 345
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Aarsland, D. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.708 · Cited by 341
Self-citationCholinergic dysfunction in diseases with Lewy bodies
Tiraboschi, P., Hansen, L. A., Alford, M., Sabbagh, M. N., Schoos, B., Masliah, E., Thal, L. J., & Corey-Bloom, J. (2000) · Neurology · doi:10.1212/wnl.54.2.407 · Cited by 328
HOW COMMON IS DEMENTIA IN PARKINSON'S DISEASE?
Brown, R. G., & Marsden, C. D. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92807-1 · Cited by 320
The association of incident dementia with mortality in PD
Levy, G., Tang, M.-X., Louis, E. D., Côté, L. J., Alfaro, B., Mejia, H., Stern, Y., & Marder, K. (2002) · Neurology · doi:10.1212/01.wnl.0000036610.36834.e0 · Cited by 297
Reading, P. J., Luce, A. K., & McKeith, I. G. (2001) · Movement Disorders · doi:10.1002/mds.1204 · Cited by 272
Manos, P. J., & Wu, R. (1994) · The International Journal of Psychiatry in Medicine · doi:10.2190/5a0f-936p-vg8n-0f5r · Cited by 260
Bryant, J., Clegg, A., Nicholson, T., McIntyre, L., De Broe, S., Gerard, K., & Waugh, N. (2001) · Health Technology Assessment · doi:10.3310/hta5010 · Cited by 246
Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates
Cummings, J. L. (1988) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198878800100106 · Cited by 206
The cognitive drug research computerized assessment system for demented patients: A validation study
Simpson, P. M., Surmon, D. J., Wesnes, K. A., & Wilcock, G. K. (1991) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930060208 · Cited by 185
Bohnen, N. I. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.038729 · Cited by 160
Benamer, H. T. S., Oertel, W. H., Patterson, J., Hadley, D. M., Pogarell, O. M., Höffken, H., Gerstner, A., & Grosset, D. G. (2003) · Movement Disorders · doi:10.1002/mds.10482 · Cited by 148
Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS
Beatty, W. W., Ryder, K., Gontkovsky, S. T., SCOTT, J., McSwan, K. L., & Bharucha, K. J. (2003) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/18.5.509 · Cited by 118
Is levodopa toxic to human substantia nigra?
Rajput, A. H., Fenton, M. E., Birdi, S., & Macaulay, R. J. B. (1997) · Movement Disorders · doi:10.1002/mds.870120503 · Cited by 109
Datla, K. P., Blunt, S. B., & Dexter, D. T. (2001) · Movement Disorders · doi:10.1002/mds.1091 · Cited by 103
Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease.
Huber, S. J., Paulson, G. W., & Shuttleworth, E. C. (1988) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.855 · Cited by 99
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease
Giladi, N., Shabtai, H., Gurevich, T., Benbunan, B. R., Anca‐Herschkovitsch, M., & Korczyn, A. D. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2003.00211.x · Cited by 99
Clegg, A. J., Scott, D. A., Sidhu, M., Hewitson, P., & Waugh, N. R. (2001) · Health Technology Assessment · doi:10.3310/hta5320 · Cited by 97
Dementia in Parkinson's disease: cause and treatment
Emre, M. (2004) · Current Opinion in Neurology · doi:10.1097/01.wco.0000137529.30750.ab · Cited by 88
Self-citationCummings, J. L. (1988) · PubMed · Cited by 79
Kostrzewa, R. M., Kostrzewa, J. P., & Brus, R. (2002) · Amino Acids · doi:10.1007/s00726-001-0110-x · Cited by 64
Richard, I. H., Justus, A. W., Greig, N. H., Marshall, F. J., & Kurlan, R. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200211000-00002 · Cited by 42
Dementia: the University of Oklahoma autopsy experience.
Leech, R. W., Brumback, R. A., Se, P., Schiffer, R. B., & Adesina, A. M. (2001) · PubMed · Cited by 7
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationClinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationDiagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Metadata
- Authors
- Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., Poewe, W., Robillard, A., Rosa, M. M., Wolters, E., Quarg, P., Tekin, S., & Lane, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-12-09
- Volume
- 351
- Issue
- 24
- Pages
- 2509-2518
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115455636
- Cited by
- 1,223
- References
- 51
- FWCI
- 49.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.